Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma
Biomedical Materials · 2024
DOI: 10.1088/1748-605x/ad1bb2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Materials, 2024. Verfasst von Muhammad Younis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammation, Immunity & Infection, Georgia State University, Institute for Biomedical Sciences, Atlanta, GA, United States of America. Hauptthemen laut MEDLINE: Anthracyclines, Brain Neoplasms, Glioblastoma, Glioma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Doctoral Research Foundation of Taizhou Polytechnic College, Innovative Research Team of Taizhou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glioblastoma (GBM) remains a challenging malignancy due to its aggressive nature and the lack of efficacious therapeutic interventions. Nanotechnology-based approaches exhibit promise in GBM treatment; however, the successful translation of these strategies from preclinical models to clinical settings is hindered by inefficient nanoparticle clearance from vital organs. Addressing this concern, we investigated the therapeutic potential of amrubicin (AMR) encapsulated within poly (lactic-co-glycolic acid) nanoparticles (AMR-PLGA-NPs) in combating temozolomide (TMZ) resistant GBM. The study demonstrated that AMR-PLGA-NPs exerted a pronounced inhibitory effect on the cellular viability and migratory capacity of TMZ-resistant GBM cells. Furthermore, these nanoparticles exhibited considerable efficacy in downregulating the PI3K/AKT signaling pathway, thereby inducing apoptosis specifically in TMZ-resistant glioma cells and glioma stem-like cells through the activation of PTEN. Notably, in vivo experimentation revealed the ability of AMR-PLGA-NPs to traverse biological barriers within murine models. Collectively, these findings underscore the potential therapeutic utility of AMR-PLGA-NPs as a versatile nanoplatform for addressing the formidable challenges posed by GBM, particularly in mitigating drug resistance mechanisms. The study substantiates the stability and safety profile of AMR-PLGA-NPs, positioning them as a promising avenue for combating drug resistance in GBM therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Inflammation, Immunity & Infection, Georgia State University, Institute for Biomedical Sciences, Atlanta, GA, United States of America.
- Department of Biochemistry and Molecular Biology, Medical School of Southeast University, Nanjing 210009, People's Republic of China.
- Shanghai Fourth People's Hospital, and School of Medicine, Tongji University, Shanghai 200120, People's Republic of China.
- Department of Zoology, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan.
- The Royal College of Surgeons in Ireland, Dublin D01F5P2, Ireland.
- The Royal College of Surgeons of England, London NW1 0RY, United Kingdom.
ORCID-Profile: Khawar Ali Shahzad
Förderung
- Doctoral Research Foundation of Taizhou Polytechnic College
- Innovative Research Team of Taizhou
- National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities
Zitieren
APA
Younis, M., Shaikh, S., Shahzad, K. A., Tan, F., Wang, Z., & Lashari, M. H. (2024). Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma. Biomedical Materials. https://doi.org/10.1088/1748-605x/ad1bb2
Vancouver
Younis M, Shaikh S, Shahzad KA, Tan F, Wang Z, Lashari MH. Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma. Biomedical Materials. 2024. doi:10.1088/1748-605x/ad1bb2
BibTeX
@article{Younis2024,
author = {Younis, Muhammad and Shaikh, Sana and Shahzad, Khawar Ali and Tan, Fei and Wang, Zhao and Lashari, Mushtaq Hussain},
title = {Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma},
journal = {Biomedical Materials},
year = {2024},
doi = {10.1088/1748-605x/ad1bb2}
}
EUVIMED